Generic Name and Formulations:
Sargramostim 250mcg/vial; lyophilized pwd for SC inj or IV infusion after reconstitution; preservative-free; 500mcg/mL; soln for SC inj or IV infusion after dilution; contains benzyl alcohol.
Indications for LEUKINE:
To speed neutrophil recovery and reduce infections after induction chemotherapy for acute myelogenous leukemia (AML) in patients ≥55yrs. To mobilize autologous hematopoietic progenitor cells into peripheral blood for collection by leukapheresis in adults with cancer. To speed myeloid recovery in non-Hodgkin's lymphoma, acute lymphoblastic leukemia (ALL), and Hodgkin's lymphoma after autologous peripheral blood progenitor cell (PBPC) or bone marrow transplantation (BMT). To speed myeloid recovery in allogeneic BMT. To treat delayed neutrophil recovery or graft failure in BMT. To increase survival in hematopoietic syndrome of acute radiation syndrome (H-ARS).
Adults and Children:
See full labeling for timing and duration of dosing, and for repeat courses of therapy. Individualize. Neutrophil recovery in AML: 250mcg/m2/day IV over 4hrs. PBPC mobilization: 250mcg/m2/day IV over 24hrs or SC once daily. Myeloid recovery post PBPC transplantation: <2yrs: not established. ≥2yrs: 250mcg/m2/day IV over 24hrs or SC once daily. Myeloid recovery in BMT: <2yrs: not established. ≥2yrs: 250mcg/m2/day IV over 2hrs. BMT failure or engraftment delay: <2yrs: not established. ≥2yrs: 250mcg/m2/day IV over 2hrs for 14 days. H-ARS (<15kg): 12mcg/kg SC once daily; (15–40kg): 10mcg/kg SC once daily; (>40kg): 7mcg/kg SC once daily. Dose modifications: see full labeling.
Allergy to yeast-derived products.
Monitor for infusion-related reactions (esp. in lung disease); reduce infusion rate by ½ if dyspnea occurs; discontinue if worsens. Fluid retention, pleural or pericardial effusions. Pulmonary infiltrates. CHF. Cardiac disease. Monitor CBC and differential twice weekly. Myeloid malignancies (discontinue if disease progresses). Monitor body weight and hydration. Use for shortest duration required. Neonates/infants: avoid benzyl alcohol-containing solns. Pregnancy. Nursing mothers: not recommended (during and for ≥2 weeks after last dose).
Granulocyte-macrophage colony stimulating factor (recombinant).
Avoid concomitant or within 24 hours preceding cytotoxic chemotherapy or radiotherapy, or within 24 hours after chemotherapy. Avoid lithium, corticosteroids, others that may enhance myeloproliferative effects.
Fever, GI disturbances, mucous membrane disorder, alopecia, asthenia, malaise, anorexia, rash/skin reactions, edema, stomatitis, high glucose, abdominal pain, low albumin, headache, hypertension, liver toxicity, infections, metabolic or GU abnormalities, pulmonary toxicity, neurotoxicity, weight loss; hypersensitivity reactions (discontinue if occur).
Single-dose vials (pwd)—5; Multi-dose vials (soln)—5
Neurology Advisor Articles
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Natalizumab Improves Cognitive Function in Multiple Sclerosis
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- Loss of Function Variants in LRRK1 and LRRK2 Not Linked to Parkinson Disease
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- ZTlido Patch for Post-Shingles Pain Launching Soon
- Managing Complications of Intrathecal Baclofen Therapy
- Deep Brain Stimulation Reduces Tremor Symptoms in Parkinson Disease
- FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid
- Prevalence of Autoimmune Encephalitis in Herpes Simplex Encephalitis Explored